Catalog No.
RHC23303
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400, IF: 1:200-1:1000, IHC: 1:200-1:1000, WB: 1:500-1:2000
Target
NEFL, Neurofilament light polypeptide, 68 kDa neurofilament protein, NF68, Neurofilament triplet L protein, NF-L, NFL
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P07196
Applications
ELISA, FCM, IF, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3A04
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis., PMID:40510879
Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab., PMID:40345115
Serum angiotensin type-1 receptor autoantibodies and neurofilament light chain as markers of neuroaxonal damage in post-COVID patients., PMID:40330487
Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis., PMID:40300121
The utility of serum neurofilament light chain in MOGAD: Current insights and future directions., PMID:40220725
Distinct prognostic implications of blood neuronal and astroglial biomarkers in neuromyelitis optica spectrum disorders versus multiple sclerosis., PMID:40175444
Secreted neurofilament light chain after neuronal damage induces myeloid cell activation and neuroinflammation., PMID:40056413
A turn-on fluorescent immunosensor for neurodegenerative disease related neurofilament light chain protein., PMID:39904887
The value of CSF diagnostic and prognostic biomarkers in NMOSD and MOGAD in real-life use., PMID:39893752
Usefulness of serum neurofilament light chain in chronic inflammatory demyelinating polyradiculoneuropathy., PMID:39874744
CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity., PMID:39869499
Neurofilament light chain levels in neuronal surface antibody-associated autoimmune encephalitis: a systematic review and meta-analysis., PMID:39856041
Serum NfL predicts outcome and secondary autoimmunity in herpes-simplex encephalitis., PMID:39842345
Neuromuscular junction visualization in paraffin-embedded thyroarytenoid muscle sections: Expanding options beyond frozen section analysis., PMID:39780862
Immunohistochemical labeling of ongoing axonal degeneration 10 days following cervical contusion spinal cord injury in the rat., PMID:39753895
Serum glycobiomarkers for chronic inflammatory demyelinating polyneuropathy., PMID:39722472
Blood-Based Biomarkers for Identifying Disease Activity in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder., PMID:39714824
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease., PMID:39705633
Effect of Natalizumab on sNfL and sGFAP Levels in Multiple Sclerosis Patients., PMID:39684862
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis., PMID:39606235
Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy., PMID:39601182
Cerebrospinal fluid levels of NfM in relation to NfL and pNfH as prognostic markers in amyotrophic lateral sclerosis., PMID:39575564
Phenotypic and oncological insights in ANNA1 autoimmunity: Age stratification and biomarker analysis., PMID:39556523
Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis., PMID:39536291
De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study., PMID:39510011
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients., PMID:39494701
Intrathecal IgG and IgM synthesis correlates with neurodegeneration markers and corresponds to meningeal B cell presence in MS., PMID:39462090
Autoimmune astrocytopathy double negative for AQP4-IgG and GFAP-IgG: Retrospective research of clinical practice, biomarkers, and pathology., PMID:39279053
Blood neurofilament light chain measurements in adults with CNS histiocytic neoplasms., PMID:39237493
Effect of alemtuzumab over sNfL and sGFAP levels in multiple sclerosis., PMID:39224593
An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease., PMID:39048548
Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients., PMID:38909525
Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study., PMID:38901371
Age-corrected neurofilament light chain ratio decreases but does not predict relapse in highly active multiple sclerosis patients initiating natalizumab treatment., PMID:38889559
Neuroaxonal damage in natalizumab-treated MS patients: The role of JCV antibody titres., PMID:38877721
Electrochemical Biosensor for Point-of-Care Testing of Low-Abundance Biomarkers of Neurological Diseases., PMID:38865206
Serum NfL and EGFR/NfL ratio mRNAs as biomarkers for phenotype and disease severity of myelin oligodendrocyte glycoprotein IgG-associated disease., PMID:38807603
The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis., PMID:38777960
Autoantibody Profile Emerged Years Before Multiple Sclerosis Diagnosis., PMID:38758535
Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study., PMID:38754397
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial., PMID:38683602
Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis., PMID:38648580
An autoantibody signature predictive for multiple sclerosis., PMID:38641750
Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder., PMID:38564996
Clinical Evaluation of Cerebrospinal Fluid p217tau and Neurofilament Light Chain Levels in Patients with Alzheimer's Disease or Other Neurological Diseases., PMID:38007650
Elevated plasma neurofilament light chain in immune-mediated neurological disorders (IMND) detected by immunomagnetic reduction (IMR)., PMID:37739331
High serum neurofilament levels are observed close to disease activity events in pediatric-onset MS and MOG antibody-associated diseases., PMID:37031551
Nogo-A Regulates the Fate of Human Dental Pulp Stem Cells toward Osteogenic, Adipogenic, and Neurogenic Differentiation., PMID:36359811
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis., PMID:35025605
Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation., PMID:34985329
For research use only. Not for human or drug use.
